Optiscan Imaging (OIL) H2 2025 earnings summary

Executive summary

• Transitioned from development to clinical validation, positioning for global healthcare market entry.

• Revealed two new devices: InForm™ for digital pathology and InSpecta™ for veterinary medicine.

• Expanded commercial footprint across US, Europe, and China, and deepened clinical partnerships.

• Achieved MVP for telepathology streaming platform and advanced AI collaborations.

Financial highlights

• FY25 revenue was $951,948, down 18% from $1,155,604 in FY24, mainly due to lower orders from Carl Zeiss Meditec.

• Other income rose 31% to $3,106,879, driven by a 142% increase in R&D incentive income to $2,410,376.

• Net loss after tax was $6,311,952, compared to $6,060,496 in FY24.

• Net assets decreased to $7,712,014 from $13,867,491, reflecting higher R&D and commercial outflows.

• No dividends declared or paid for the year.

Outlook and guidance

• Focus on obtaining certifications and clinical validation data for new devices.

• Ongoing clinical studies in Australia, Germany, and the US to support regulatory submissions, including FDA.

• Anticipated commercial launch of new devices following regulatory approvals.